Neo Nisidina (Paracetamol, Acetylsalicylic Acid, Caffeine)

Paracetamol acts centrally to inhibit cyclo‑oxygenase and lower prostaglandin synthesis, producing analgesic and antipyretic effects. Acetylsalicylic acid irreversibly blocks COX‑1 and COX‑2, further reducing prostaglandins and adding anti‑inflammatory activity. Caffeine antagonises adenosine receptors, which enhances the pain‑relieving action of the other two agents and reduces fatigue.

The appropriate dose of Neo Nisidina is determined by the prescribing healthcare professional based on the patient’s age, weight, clinical condition and any concomitant medications. Because the product contains a fixed combination of three active ingredients, the prescriber selects the dosage that balances efficacy with safety for each individual.

Safety in pregnancy and lactation has not been fully established for this fixed‑dose combination. Paracetamol is generally considered low risk, but acetylsalicylic acid can affect fetal circulation and platelet function, and caffeine crosses the placenta. Women who are pregnant, planning pregnancy or breastfeeding should discuss use with their doctor before taking Neo Nisidina.

To place an enquiry, visit the Neo Nisidina product page on gnhindia.com and submit the required quantity using the online form. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any temperature‑control requirements) and the necessary import documentation.

Compared with single‑ingredient products such as plain paracetamol or ibuprofen, Neo Nisidina adds acetylsalicylic acid for additional anti‑inflammatory effect and caffeine to boost analgesia and reduce fatigue. This multi‑component formulation can provide faster and more pronounced pain relief for certain patients, but it also introduces the need to consider aspirin‑related contraindications and caffeine‑related side effects.

Neo Nisidina should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the container tightly closed and out of direct sunlight. Do not store in a refrigerator or freezer, as temperature extremes can affect tablet integrity.

Neo Nisidina is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional. It is intended for use as needed for pain or fever, following the dosage instructions provided by the prescriber.

Serious risks include gastrointestinal bleeding, especially when combined with other NSAIDs or anticoagulants; severe allergic reactions such as anaphylaxis; liver toxicity from excessive paracetamol exposure; and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they notice unusual bleeding, rash, jaundice or breathing difficulties.

Neo Nisidina is contraindicated in individuals with known hypersensitivity to aspirin, paracetamol or caffeine, in patients with active peptic ulcer disease, severe liver impairment, or in children with viral infections due to the risk of Reye's syndrome. It should also be avoided by anyone taking anticoagulant therapy without medical supervision.